Details
Stereochemistry | RACEMIC |
Molecular Formula | C19H21N3S |
Molecular Weight | 323.455 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(CN(C)C)CN1C2=CC=CC=C2SC3=C1C=C(C=C3)C#N
InChI
InChIKey=SLFGIOIONGJGRT-UHFFFAOYSA-N
InChI=1S/C19H21N3S/c1-14(12-21(2)3)13-22-16-6-4-5-7-18(16)23-19-9-8-15(11-20)10-17(19)22/h4-10,14H,12-13H2,1-3H3
Molecular Formula | C19H21N3S |
Molecular Weight | 323.455 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
Cyamemazine (Tercian), also known as cyamepromazine, is a typical antipsychotic drug of the phenothiazine class used primarily in the treatment of schizophrenia and psychosis-associated anxiety. Cyamemazine actually behaves like an atypical antipsychotic, due to its potent anxiolytic effects and lack of extrapyramidal side effects. Cyamemazine is used for the treatment of chronic psychotic states, anxiety, major depression.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P21728 Gene ID: 1812.0 Gene Symbol: DRD1 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/12527336 |
3.8 nM [Ki] | ||
Target ID: CHEMBL234 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12527336 |
2.5 nM [Ki] | ||
Target ID: P28223 Gene ID: 3356.0 Gene Symbol: HTR2A Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/12527336 |
1.5 nM [Ki] | ||
Target ID: P28335 Gene ID: 3358.0 Gene Symbol: HTR2C Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/12527336 |
12.0 nM [Ki] | ||
Target ID: CHEMBL2095203 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12527336 |
2.3 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | TERCIAN Approved UseChronic psychotic states (schizophrenia, chronic non-schizophrenic delusions: paranoid delusions, chronic hallucinatory psychoses). |
|||
Primary | TERCIAN Approved UseShort-term symptomatic treatment of adult anxiety in case of failure of usual therapies. |
|||
Primary | TERCIAN Approved UseIn combination with an antidepressant, short-term treatment of some severe forms of major depressive episode. |
|||
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Hypertonia and malignant hyperthermia due to morphine and neuroleptic. | 1981 Feb 14 |
|
Transient ST segment elevation in right precordial leads induced by psychotropic drugs: relationship to the Brugada syndrome. | 2001 Jan |
|
Affinity of cyamemazine, an anxiolytic antipsychotic drug, for human recombinant dopamine vs. serotonin receptor subtypes. | 2003 Feb 1 |
|
[Catatonia de novo, report on a case: immediate vital prognosis and psychiatric prognosis in longer term]. | 2003 Jan-Feb |
|
A positron emission tomography (PET) study of cerebral dopamine D2 and serotonine 5-HT2A receptor occupancy in patients treated with cyamemazine (Tercian). | 2005 Jul |
|
Contrasting action of flavonoids on phototoxic effects induced in human skin fibroblasts by UVA alone or UVA plus cyamemazine, a phototoxic neuroleptic. | 2005 May |
|
False-positive results in the detection of methadone in urines of patients treated with psychotropic substances. | 2005 Nov |
|
Affinity of cyamemazine metabolites for serotonin, histamine and dopamine receptor subtypes. | 2008 Jan 14 |
|
[Prescribing patterns of antipsychotics in 13 French psychiatric hospitals]. | 2009 Apr |
|
Buprenorphine-related deaths: unusual forensic situations. | 2010 Nov |
Patents
Sample Use Guides
Oral: 25-600 mg daily in 2 or 3 divided doses with larger doses taken at night. Intramuscular: 25-200 mg daily.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/12527336
Binding to receptors was carried out using radioligand binding assay. Suspension of cells, expressing the receptor was incubated with cyamemazine and a reference radioligand. At the end of incubation period, membranes or cells were rapidly filtered under vacuum conditions through glass fiber filters. Bound radioactivity was measured with a scintillation counter. Each competition concentration-response curve was determined in duplicated using cyamemazine concentration spanning from 0.03 nM to 30-100 uM
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:12:41 UTC 2023
by
admin
on
Fri Dec 15 16:12:41 UTC 2023
|
Record UNII |
A2JGV5CNU4
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29578
Created by
admin on Fri Dec 15 16:12:41 UTC 2023 , Edited by admin on Fri Dec 15 16:12:41 UTC 2023
|
||
|
WHO-VATC |
QN05AA06
Created by
admin on Fri Dec 15 16:12:41 UTC 2023 , Edited by admin on Fri Dec 15 16:12:41 UTC 2023
|
||
|
WHO-ATC |
N05AA06
Created by
admin on Fri Dec 15 16:12:41 UTC 2023 , Edited by admin on Fri Dec 15 16:12:41 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
746
Created by
admin on Fri Dec 15 16:12:41 UTC 2023 , Edited by admin on Fri Dec 15 16:12:41 UTC 2023
|
PRIMARY | |||
|
DTXSID80863190
Created by
admin on Fri Dec 15 16:12:41 UTC 2023 , Edited by admin on Fri Dec 15 16:12:41 UTC 2023
|
PRIMARY | |||
|
21877
Created by
admin on Fri Dec 15 16:12:41 UTC 2023 , Edited by admin on Fri Dec 15 16:12:41 UTC 2023
|
PRIMARY | RxNorm | ||
|
DB09000
Created by
admin on Fri Dec 15 16:12:41 UTC 2023 , Edited by admin on Fri Dec 15 16:12:41 UTC 2023
|
PRIMARY | |||
|
C79120
Created by
admin on Fri Dec 15 16:12:41 UTC 2023 , Edited by admin on Fri Dec 15 16:12:41 UTC 2023
|
PRIMARY | |||
|
m3943
Created by
admin on Fri Dec 15 16:12:41 UTC 2023 , Edited by admin on Fri Dec 15 16:12:41 UTC 2023
|
PRIMARY | Merck Index | ||
|
100000083726
Created by
admin on Fri Dec 15 16:12:41 UTC 2023 , Edited by admin on Fri Dec 15 16:12:41 UTC 2023
|
PRIMARY | |||
|
222-594-2
Created by
admin on Fri Dec 15 16:12:41 UTC 2023 , Edited by admin on Fri Dec 15 16:12:41 UTC 2023
|
PRIMARY | |||
|
SUB06836MIG
Created by
admin on Fri Dec 15 16:12:41 UTC 2023 , Edited by admin on Fri Dec 15 16:12:41 UTC 2023
|
PRIMARY | |||
|
62865
Created by
admin on Fri Dec 15 16:12:41 UTC 2023 , Edited by admin on Fri Dec 15 16:12:41 UTC 2023
|
PRIMARY | |||
|
Cyamemazine
Created by
admin on Fri Dec 15 16:12:41 UTC 2023 , Edited by admin on Fri Dec 15 16:12:41 UTC 2023
|
PRIMARY | |||
|
CHEMBL2104153
Created by
admin on Fri Dec 15 16:12:41 UTC 2023 , Edited by admin on Fri Dec 15 16:12:41 UTC 2023
|
PRIMARY | |||
|
C028457
Created by
admin on Fri Dec 15 16:12:41 UTC 2023 , Edited by admin on Fri Dec 15 16:12:41 UTC 2023
|
PRIMARY | |||
|
A2JGV5CNU4
Created by
admin on Fri Dec 15 16:12:41 UTC 2023 , Edited by admin on Fri Dec 15 16:12:41 UTC 2023
|
PRIMARY | |||
|
3546-03-0
Created by
admin on Fri Dec 15 16:12:41 UTC 2023 , Edited by admin on Fri Dec 15 16:12:41 UTC 2023
|
PRIMARY | |||
|
1148
Created by
admin on Fri Dec 15 16:12:41 UTC 2023 , Edited by admin on Fri Dec 15 16:12:41 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
ENANTIOMER -> RACEMATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |